Abbott Laboratories reported second-quarter 2026 results with reported sales growth of 13.0 percent and adjusted diluted EPS of $1.31. The company raised its full-year 2026 adjusted diluted EPS guidance to a range of $5.45 to $5.60, compared to the previous range of $5.38 to $5.58. Abbott returned $2.1 billion to shareholders in the second quarter through dividends and share repurchases. Abbott Laboratories is a global healthcare leader providing diagnostics, medical devices, nutritionals, and branded generic medicines.

Abbott Laboratories shareholders approved the 2026 Incentive Stock Program, which authorizes the issuance of up to 140 million common shares to replace the company's existing 2017 program. Additionally, the company expanded its Board of Directors to thirteen members and appointed Kevin Conroy to the Board. These updates refresh Abbott's equity compensation framework and governance structure for the upcoming ten-year term.

A federal court has preliminarily approved a proposed settlement in the consolidated shareholder derivative litigation regarding Abbott Laboratories' infant formula issues. This development marks a significant step toward resolving legal claims against the company's directors and officers, potentially reducing long-term legal uncertainty and liability for the firm.

Abbott Laboratories announced its first quarter 2026 results of operations, officially disclosing the company's financial performance for the period. This filing is significant for investors as it provides the basis for evaluating the company's quarterly growth and management's ability to meet performance expectations using both GAAP and non-GAAP metrics.

Abbott Laboratories has completed its acquisition of Exact Sciences Corporation, with Exact Sciences shareholders receiving $105.00 per share in cash. This transaction represents a significant strategic expansion for Abbott, as Exact Sciences will now operate as a wholly owned subsidiary.

Abbott Laboratories has completed a $20 billion issuance of senior notes across various maturities to finance its acquisition of Exact Sciences Corporation and repay associated debt. This massive capital raise provides the liquidity needed for the merger but will significantly increase the company's long-term debt profile and introduces redemption risks if the deal fails to close by early 2027.